Download Files:
BTX161
$380 – $2,850
Products Details
Product Description
– BTX161, a Thalidomide analog, is a potent CKIα degrader. BTX161 mediates degradation of CKIα better than Lenalidomide in human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2[1].
Web ID
– HY-120084
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C15H16N2O3
References
– [1]Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018;175(1):171-185.e25.
CAS Number
– 2052301-24-1
Molecular Weight
– 272.30
Compound Purity
– 98.58
SMILES
– O=C([C@@H](N(CC1=C2C=CC=C1C)C2=O)CCC3)NC3=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Casein Kinase
Pathway
– Cell Cycle/DNA Damage;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
